Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

ents with LV systolic dysfunction."

About Heart Failure

Heart failure is a chronic and progressive condition in which the heart cannot efficiently pump blood to meet the body's oxygen demands. The American Heart Association estimates that about 6 million Americans are living with heart failure, with 550,000 new cases diagnosed annually. Heart failure accounts directly for 55,000 deaths and indirectly for an additional 230,000 deaths in the United States each year. Heart failure is the underlying reason for approximately 12 to 15 million annual visits to physicians and 6.5 million annual hospital days.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead drug candidate, bucindolol, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to bucindolol. ARCA biopharma, in partnership with Laboratory Corporation of America (NYSE: LH), is developing a companion genetic test for bucindolol. For more information please visit http://www.arcabiopharma.com.


'/>"/>
SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Market ... formed a strategic alliance with Designing Gig LLC to ... clients. , “Forging this alliance with Designing ... Now we can extend a comprehensive, end-to-end, digital solution ... strategy, and execution,” said Chuck Miller, president of The ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... LLC ( http://www.trimarkpublications.com ), a global leader in the ... newly published Regenerative Medicine Markets report that ... $3 billion in 2010 and is expected to reach ... to treat injuries and diseases with specially-grown tissues by ...
... YOKOHAMA, Japan, September 1, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
Cached Biology Technology:Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6Medisafe 1 Technologies Announces 1-5 Stock Dividend 2Medisafe 1 Technologies Announces 1-5 Stock Dividend 3Medisafe 1 Technologies Announces 1-5 Stock Dividend 4Medisafe 1 Technologies Announces 1-5 Stock Dividend 5Medisafe 1 Technologies Announces 1-5 Stock Dividend 6
(Date:3/10/2015)... -- Continuing its 167-year history of offering the Best, the ... Eye Scanning Password Authenticator , a device that confirms ... or sensitive data. Employing the same biometric ... device has a small camera that scans and saves ... them into an encrypted ID that cannot be forged ...
(Date:3/10/2015)... March 10, 2015  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the ... smart wallet has been named the "Number One ... Rethink Modern ( http://www.rethinkmodern.com/ ) is ... your home and lifestyle that have a unique function ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... large, multisite trial designed to examine the safety ... to prevent HIV infection has opened to volunteer ... of Allergy and Infectious Diseases (NIAID), part of ... among various research institutions in Africa and the ...
... brain-clogging deposits that cause such disorders as Alzheimer's ... out how to capture and "micromanipulate" the single ... aim is to understand the detailed assembly process ... basic understanding, they said, could lead to approaches ...
Cached Biology News: MetaChip provides quick, efficient toxicity screening of potential drugs 2Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
... and easy to use Ascent ... all members of the Ascent ... a clear and easy-to-follow approach ... user-friendly and highly sophisticated data ...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Biology Products: